Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 20;11:2087. doi: 10.3389/fimmu.2020.02087

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Silvane, Celias, Romagnoli, Maletto, Sanchez Vallecillo, Chiapello, Palma, Allemandi, Sanabria, Pruzzo, Motrán and Cervi.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

IL-17A neutralization decreased the efficacy of FhKTM/CpG-ODN/Coa-ASC16 vaccination. (A) Mice were administered with anti-IL-17A antibody and the corresponding isotype control (250 μg i.p) 2 days before and after infections. (B) Kaplan–Meier graphs show survival curves for those mice immunized three times with FhKTM/CpG-ODN/Coa-ASC16 or PBS. IL-17A-mAb and corresponding isotype control (mAb Isotype) were administered 2 days both before and after infection. dpi: days post infection. (C) Left: infected liver showing marked enlargement with distended gallbladder (thick arrow), areas of fibrosis extending (asterix), and larvae on the parenchyma surface (notched arrow). FhKTM/CpG-ODN/Coa-ASC16: liver showing normal size with no observed lesion except in 1 out of 8 mice. Infected-mAb-IL-17A: the liver showing marked severe macroscopic damage (thin arrow) and presented irregular surface denoting hepatic fibrosis (asterix). The presence of larvae on the surface can be seen (notched arrow). FhKTM/CpG-ODN/Coa-ASC16 -mAb-IL-17A: The hepatic parenchyma is severely reduced, firm, and presents an irregular surface (thin arrow) denoting hepatic fibrosis (asterix). Abnormal gross appearance of the distended gallbladder with presence of blood inside (thick arrow). infected-mAb Isotype: the liver is smaller than normal and presents irregular surface tissue denoting hypertrophied (thin arrow) and replaced with fibrosis (asterix) and a fluke released after the rupture of the gallbladder (notched arrow). FhKTM/CpG-ODN/Coa-ASC16-mAb Isotype: liver showing no apparent gross pathology except for in 2 out of 8 mice. Right, the score damage was assessed by the extensión of liver damaged (score range 0 to 5). The data shown are pooled from two independent experiments with total (n = 5–8 per group). The statistical differences among survival curves were calculated by using Mantel–Cox test. ***p < 0.001.